Prodrug compounds with isoleucine
View Patent ↗The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide having an isoleucine residue, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by an enzyme associated with the target cell. Methods of making and using the compounds are also disclosed.
1. In a method of making a prodrug, a method of removing free therapeutic agent comprising:
(1) coupling an optionally protected stabilizing group-oligopeptide conjugate with the free therapeutic agent,
(2) contacting the product of step (1) with a polymeric resin to bind free therapeutic agent remaining after step (1) and to form a therapeutic agent-polymeric resin complex, wherein the polymeric resin is polystyrene methylisocyanate, or polystyrene sulfonyl chloride, and
(3) removing the therapeutic agent-polymeric resin complex.
2. The method of claim 1 wherein the optionally protected stabilizing group-oligopeptide conjugate includes an oligopeptide of the formula (AA) n -AA 3 -AA 2 -AA 1 , wherein:
each AA independently represents an amino acid,
n is 0 or 1, and when n is 1, then (AA) n is AA 4 which represents any amino acid,
AA 3 represents isoleucine,
AA 2 represents any amino acid, and
AA 1 represents any amino acid.
3. The method of claim 1 , wherein the therapeutic agent is selected from the group consisting of Doxorubicin, Daunorubicin, Vinblastine, Vincristine, Calicheamicin, Etoposide, Etoposide phosphate, CC-1065, Duocarmycin, KW-2189, Methotrexate, Methopterin, Aminopterin, Dichloromethotrexate, Docetaxel, Paclitaxel, Epithiolone, Combretastatin, Combretastatin A4 Phosphate, Dolastatin 10, Dolastatin 11, Dolastatin 15, Topotecan, Camptothecin, Mitomycin C, Porfiromycin, 5-Fluorouracil, 6-Mercaptopurine, Fludarabine, Tamoxifen, Cytosine arabinoside, Adenosine Arabinoside, Colchicine, Cisplatin, Carboplatin, Bleomycin, Melphalan, chloroquine, and cyclosporin A.
4. The method of claim 1 , wherein the therapeutic agent is Daunorubicin or Doxorubicin.
5. The method of claim 1 , wherein the therapeutic agent is Doxorubicin.
6. In a method of making a prodrug, a method of removing free therapeutic agent comprising:
(1) coupling an optionally protected stabilizing group-oligopeptide conjugate with the free therapeutic agent to produce a product mixture comprising a prodrug of the therapeutic agent and remaining free therapeutic agent,
(2) contacting the product of step (1) with a polymeric resin having isocyanate or sulfonyl groups to bind free therapeutic agent remaining after step (1) and to form a therapeutic agent-polymeric resin complex, wherein the polymeric resin is selected from the group consisting of polystyrene isocyanate, polystyrene thioisocyanate, polystyrene methylthioisocyanate, polystyrene methylsulfonyl chloride and polystyrene benzaldehyde; and
(3) removing the therapeutic agent-polymeric resin complex.
7. The method of claim 6 wherein the optionally protected stabilizing group-oligopeptide conjugate includes an oligopeptide of the formula (AA) n -AA 3 -AA 2 -AA 1 , wherein:
each AA independently represents an amino acid,
n is 0 or 1, and when n is 1, then (AA) n is AA 4 which represents any amino acid,
AA 3 represents isoleucine,
AA 2 represents any amino acid, and
AA 1 represents any amino acid.
8. The method of claim 6 , wherein the therapeutic agent is selected from the group consisting of Doxorubicin, Daunorubicin, Vinblastine, Vincristine, Calicheamicin, Etoposide, Etoposide phosphate, CC-1065, Duocarmycin, KW-2189, Methotrexate, Methopterin, Aminopterin, Dichloromethotrexate, Docetaxel, Paclitaxel, Epithiolone, Combretastatin, Combretastatin A4 Phosphate, Dolastatin 10, Dolastatin 11, Dolastatin 15, Topotecan, Camptothecin, Mitomycin C, Porfiromycin, 5-Fluorouracil, 6-Mercaptopurine, Fludarabine, Tamoxifen, Cytosine arabinoside, Adenosine Arabinoside, Colchicine, Cisplatin, Carboplatin, Bleomycin, Melphalan, chloroquine, and cyclosporin A.
9. The method of claim 6 , wherein the therapeutic agent is Doxorubicin.
10. The method of claim 6 , wherein the therapeutic agent is linked to the resin by a urea or sulfonamide group.